Clinical trials: Second Cancer
Carcinoma, Non-Small-Cell Lung
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent…
- Trial name
- NCT00806819
- Testing
- Nintedanib (BIBF1120), Pemetrexed, B12
- Where
- 163 sites in United States, Argentina and 30 more
- Volunteers
- 718 people
- Sponsor
- Boehringer Ingelheim
Advanced or Metastatic CRC
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer
To assess the effectiveness and safety of utidelone injection in patients with advanced or metastatic colorectal cancer (CRC) as a phase II trial
- Trial name
- NCT03906565
- Testing
- utidelone injection
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Triple-negative Breast Cancer
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
The main purpose of this study was to assess the antitumor activity of three combinations: i) LAG525 + spartalizumab; ii) LAG525 + spartalizumab + carboplatin, and iii) LAG525 + carboplatin in participants with advanced…
- Trial name
- NCT03499899
- Testing
- LAG525, PDR001, Carboplatin
- Where
- 33 sites in United States, Argentina and 15 more
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Post-Operative Ileus
Asimadoline for the Treatment of Post-Operative Ileus
The purpose of this study is to evaluate the safety and efficacy of asimadoline in patients who have undergone a laparoscopic segmental colectomy and determine whether it reduces the time to recovery of bowel function compared to…
- Trial name
- NCT00443040
- Testing
- Asimadoline
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tioga Pharmaceuticals
Non-Squamous Non-Small Cell Lung Cancer
A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer
This single arm study will assess the safety and efficacy of Tarceva monotherapy in patients with advanced non-small cell lung cancer. Patients will receive Tarceva 150mg p.o. daily.
- Trial name
- NCT01066884
- Testing
- erlotinib [Tarceva]
- Where
- 2 sites in Russia
- Volunteers
- 5 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of TLC388 (Lipotecan) as a second line treatment in subjects with advanced Hepatocellular Carcinoma.
- Trial name
- NCT02267213
- Testing
- Lipotecan
- Where
- 12 sites in China, Taiwan
- Volunteers
- 29 people
- Sponsor
- Taiwan Liposome Company
Advanced HER2-positive Breast Cancer
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
The phase Ib part of the trial will assess the MTD of AUY922 in combination with Trastuzumab in patients with Trastuzumab-refractory locally advanced or metastatic HER2+.
- Trial name
- NCT01271920
- Testing
- AUY922, Trastuzumab
- Where
- 16 sites in United States, France and 6 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
KRAS Positive Patients With Non-small Cell Lung Cancer, Squamous Cell Non-small Cell Lung Cancer
A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation positive or squamous cell non-small cell lung cancer (NSCLC) who…
- Trial name
- NCT02283320
- Testing
- BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
- Where
- 32 sites in United States, Russia
- Volunteers
- 69 people
- Sponsor
- BIND Therapeutics
Carcinoma, Non-Small-Cell Lung
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
This randomised, open-label phase III trial will be performed in patients with advanced squamous cell carcinoma of the lung requiring second-line treatment after receiving first-line platinum-based chemotherapy.
- Trial name
- NCT01523587
- Testing
- afatinib, erlotinib
- Where
- 192 sites in United States, Argentina and 21 more
- Volunteers
- 795 people
- Sponsor
- Boehringer Ingelheim
Metastatic Prostate Cancer, Prostate Adenocarcinoma
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men…
- Trial name
- CONTACT-02 (NCT04446117)
- Testing
- Cabozantinib, Atezolizumab, Abiraterone Acetate
- Where
- 280 sites in United States, Argentina and 25 more
- Volunteers
- 575 people
- Sponsor
- Exelixis
Hepatocellular Carcinoma
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
The purpose of this study is to determine whether TAC-101 as a second line therapy for participants who received Sorafenib as first line therapy is effective in slowing tumor activity in patients with advanced hepatocellular…
- Trial name
- NCT00687596
- Testing
- TAC-101
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Taiho Oncology, Inc.
Breast Cancer
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
Clinical trial in breast cancer patients with bone metastases pretreated for approximately 1 year with a standard zoledronic acid regimen.
- Trial name
- NCT00320710
- Testing
- Zoledronic acid
- Where
- 92 sites in United States
- Volunteers
- 416 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia
Amonafide in Combination With Cytarabine in Secondary AML
This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.
- Trial name
- NCT00273884
- Testing
- Amonafide L-Malate, Cytarabine
- Where
- 21 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Xanthus Pharmaceuticals, Inc.
Endometrial Cancer
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Open-label, randomized, active-controlled, two-arm Phase III study to compare the efficacy and safety of AEZS-108 and doxorubicin.
- Trial name
- ZoptEC (NCT01767155)
- Testing
- AEZS-108 / zoptarelin doxorubicin, doxorubicin
- Where
- 123 sites in United States, Austria and 20 more
- Volunteers
- 511 people
- Sponsor
- AEterna Zentaris
Non-small-cell Lung Cancer
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
- Trial name
- NCT01138163
- Where
- 53 sites in United States, Georgia and 3 more
- Volunteers
- 121 people
- Sponsor
- Peregrine Pharmaceuticals
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy
This prospective, multicenter observational study will evaluate the efficacy, safety, and tolerability of Tarceva (erlotinib) as second-line treatment in patients with locally advanced or metastatic non-small cell lung cancer…
- Trial name
- TIME (NCT01664533)
- Testing
- Erlotinib
- Where
- 21 sites in Belgium
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer
This study is designed as Phase II/III. Phase II is aimed to evaluate safety and efficacy of IRIS, and feasibility of FOLFIRI. Phase III is aimed to verify inferiority of the progression free survival of IRIS in comparison with…
- Trial name
- NCT00284258
- Testing
- CPT-11 and TS-1, CPT-11, 5-FU and l-LV
- Where
- Japan
- Volunteers
- 426 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus
The purpose of this observational study is to estimate the overall survival (OS) rates in the overall study population treated with nivolumab in the second and third line setting in real world clinical practice in Greece and…
- Trial name
- LUCENCE (NCT05034926)
- Where
- 2 sites in Cyprus, Greece
- Volunteers
- 212 people
- Sponsor
- Bristol-Myers Squibb
Anovulation, Oligo-ovulation
Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women
This is an open-label, parallel-group, randomized, multicenter Phase III trial to compare the efficacy and safety of a single 250 microgram (mcg) subcutaneous dose of MSJ-0011 to a single 5,000 international units (IU)…
- Conditions
- Anovulation, Oligo-ovulation, Hypothalamic-pituitary Dysfunction, Polycystic Ovarian Syndrome
- Trial name
- NCT01653743
- Testing
- MSJ-0011, urinary hCG (u-hCG), Follitropin alpha
- Where
- 6 sites in Japan
- Volunteers
- 81 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Cancer, Ovarian Cancer
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
This study will assess the effect of IT-101 on delaying cancer progression in patients with platinum sensitive ovarian cancer.
- Conditions
- Cancer, Ovarian Cancer, Solid Tumor
- Trial name
- NCT00753740
- Testing
- IT-101 (12mg/m2/dose), IT-101 (15mg/m2/dose)
- Where
- 7 sites in United States
- Sponsor
- NewLink Genetics Corporation